NOVEL IMMUNOTOXIN AND IGF THERAPY FOR STRABISMUS

新型免疫毒素和 IGF 治疗斜视

• 批准号: 8172784
• 负责人: Michael J Mustari
• 金额: $ 15.51万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8172784
• 关键词: Child; Computer Retrieval of Information on Scientific Projects Database; Development; Eye; Funding; Goals; Grant; Growth; Growth Factor; Immunotoxins; Infant; Institution; Insulin-Like Growth Factor I; Laboratories; Lead; Left; Macaca; Monkeys; Muscle; Myopathy; Operative Surgical Procedures; Research; Research Personnel; Resources; Somatomedins; Source; Strabismus; United States; United States National Institutes of Health; Vision; bone morphogenic protein; infancy; muscle strength; novel

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. At least 3% of children born in the United States is afflicted with strabismus or misaligned eyes. Left untrearted infantile strabismus will lead to loss of visual function. The goal of this project is to develop novel treatments for eye muscle disorders associated with developmental or acquired strabismus. Our approach is to evaluate promising new treatment options for adjusting eye muscle strength. We have made significant progess using slow-release growth factor pellets including insulin-like growth factor (IGF-I) and Bone Morphogenic protein (BMP-I) placed on eye muscles of macaques. For example, we have found the IGF-I produces significant and selective eye muscle growth fro treated muscles of infant monkeys. We have also demonstratred that we can alter eye alignment of monkeys with artificially induced strabismus. Setting up a new laboratory at WaNPRC in association with the P.I.'s move from Yerkes NPRC to WaNPRC has been a major part of the progress during the last year. If successful our studies could provide an alternative to surgery for treating under or over-acting muscles associated with strabismus.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 在美国出生的儿童中，至少有3%患有斜视或眼睛错位。 婴儿左斜视不治疗会导致视功能丧失。 该项目的目标是开发与发育性或后天性斜视相关的眼肌疾病的新疗法。 我们的方法是评估有前途的新的治疗方案，以调整眼部肌肉力量。 我们已经取得了显着的成功，使用缓释生长因子丸，包括胰岛素样生长因子（IGF-I）和骨形态发生蛋白（BMP-I）放置在猕猴的眼肌。 例如，我们已经发现IGF-I对处理的幼猴肌肉产生显著的和选择性的眼肌生长。 我们还证明了我们可以改变人工诱导斜视的猴子的眼睛对准。与P.I.合作在WaNPRC建立新的实验室。从耶基斯NPRC转移到WaNPRC是去年进展的主要部分。 如果成功，我们的研究可以提供一种替代手术治疗与斜视相关的肌肉不足或过度作用。